

ASX RELEASE

8 October 2020

First Human Dose in Phase 1 Clinical Trial of AMP945

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to announce the dosing of the first subjects in its Phase 1 clinical trial of AMP945, the Company’s experimental Focal Adhesion Kinase inhibitor, which is being developed for difficult-to-treat cancers and fibrotic diseases.

“Dosing the first human subject with AMP945 is a transformative milestone for Amplia and one that has been the key focus for the company”, said Chief Executive Officer, Dr John Lambert. “We expect that this trial will provide the foundation upon which we can build parallel clinical programs in cancer and fibrosis and we are delighted that we have taken this significant step.”

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

About the Phase 1 Trial

The trial is a conventional randomised, placebo-controlled clinical trial which is designed to evaluate the safety and tolerability profile of AMP945 in healthy volunteers. Pharmacokinetics, or how AMP945 is absorbed and excreted by humans, will also be assessed. Additionally, some subjects in the trial will have samples tested to compare the drug levels in blood with the degree of FAK inhibition.

The trial will enrol up to 64 volunteers and is divided into three parts. In Part A, volunteers will be given single ascending single oral doses of AMP945 or placebo. In Part B, the effect of food on the oral absorption of AMP945 will be assessed and in Part C, volunteers will be given multiple ascending oral doses of AMP945 or placebo. The Company expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021. Subject to the results of the Phase 1 trial, the Company plans to progress AMP945 into Phase 2 clinical testing in patients towards the end of 2021.

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company (ASX:ATX) advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer therapy and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com